An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Authors: Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., ... & Pruijssers, A. J.
Published: July 14, 2020
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.
We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.
To continue reading the full article please follow the link: https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?source=nejmgrouplinkedin&medium=organic-social&fbclid=IwAR1m_eu5fk0N__7YvYgXS4lqD8f5Lb4KfpWDA3jy1ow8rbBz6F7eMyf4eks#article_citing_articles
PDF version: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483?articleTools=true